PE20211313A1 - Piperidinil-3-(ariloxi)propanamidas y propanoatos - Google Patents
Piperidinil-3-(ariloxi)propanamidas y propanoatosInfo
- Publication number
- PE20211313A1 PE20211313A1 PE2020001318A PE2020001318A PE20211313A1 PE 20211313 A1 PE20211313 A1 PE 20211313A1 PE 2020001318 A PE2020001318 A PE 2020001318A PE 2020001318 A PE2020001318 A PE 2020001318A PE 20211313 A1 PE20211313 A1 PE 20211313A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- substituted
- optional substituents
- alkyl
- independently selected
- Prior art date
Links
- 125000001475 halogen functional group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 102000008858 Somatostatin receptor 4 Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 2
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 abstract 2
- -1 (3-methylpyridin-2-yl) oxy Chemical group 0.000 abstract 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Abstract
Referido a un compuesto de formula 1, o una sal farmaceuticamente aceptable este donde: X1 se selecciona de N y CR1; X2 se selecciona de N y CR2; X3 se selecciona de N y CR3; y X4 se selecciona de N y CR4; X13 es NR13 y X14 es CR15R16 o X13 es CH2 y X14 es NR14; L es NR8 y O; r se selecciona de 0 y 1; s se selecciona de 0 y 1; R5 se selecciona de (a) hidrogeno, halo, hidroxi y ciano; y (b) alquilo C1-4, cicloalquilo C3-6 y alcoxi C1-4, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, oxo y fenilo que esta sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; cada R6 y R7 se selecciona independientemente halo y alquilo C1-3, o R6 y R7, junto con el atomo de carbono al que estan unidos, forman un cicloalcan-C3-4-1,1-diilo; R9 y R10 se seleccionan cada uno independientemente de a) H, halo, hidroxi y ciano; (b) alquilo C1-4, cicloalquilo C3-6 y alcoxi C1-4, cada uno sustituido con 0 a 3 sustituyentes opcionales; y (c) fenilo y heteroarilo C1-5, cada uno sustituido con 0 a 3 sustituyentes opcionales; entre otros R11 y R12 se seleccionan cada uno independientemente de (a) H, halo, hidroxi y ciano; y (b) alquilo C1-4, cicloalquilo C3-6 y alcoxi C1-4, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; o, ente otros. Un compuesto seleccionado es 2,2-dimetil-N-(1-metilpiperidin-4-il)-3-((3-metilpiridin-2-il)oxi)propanamida. Dicho compuesto es derivado de piperidinil-3-(ariloxi)propanamida y propanoatos y son moduladores del receptor de somatostatina 4 (SSTR4). Tambien se refiere a su so en el tratamiento de una enfermedad, trastorno o afeccion que se selecciona de enfermedad de Alzheimer, depresion, ansiedad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862637295P | 2018-03-01 | 2018-03-01 | |
PCT/US2019/020086 WO2019169153A1 (en) | 2018-03-01 | 2019-02-28 | Piperidinyl-3-(aryloxy)propanamides and propanoates |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211313A1 true PE20211313A1 (es) | 2021-07-22 |
Family
ID=65763866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001318A PE20211313A1 (es) | 2018-03-01 | 2019-02-28 | Piperidinil-3-(ariloxi)propanamidas y propanoatos |
Country Status (21)
Country | Link |
---|---|
US (2) | US11045457B2 (es) |
EP (1) | EP3759094A1 (es) |
JP (2) | JP7297776B2 (es) |
KR (1) | KR20200138245A (es) |
CN (1) | CN112236423B (es) |
AR (1) | AR114421A1 (es) |
AU (1) | AU2019228568A1 (es) |
BR (1) | BR112020017644A2 (es) |
CA (1) | CA3092450A1 (es) |
CL (1) | CL2020002257A1 (es) |
EA (1) | EA202092054A1 (es) |
EC (1) | ECSP20062464A (es) |
IL (1) | IL276998B2 (es) |
MX (1) | MX2020009062A (es) |
PE (1) | PE20211313A1 (es) |
PH (1) | PH12020551359A1 (es) |
SG (1) | SG11202008398XA (es) |
TW (1) | TWI834637B (es) |
UA (1) | UA126829C2 (es) |
WO (1) | WO2019169153A1 (es) |
ZA (1) | ZA202005438B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI834637B (zh) * | 2018-03-01 | 2024-03-11 | 日商武田藥品工業有限公司 | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 |
GB201901559D0 (en) | 2019-02-05 | 2019-03-27 | Syngenta Crop Protection Ag | Herbicidal compositions |
WO2021143680A1 (zh) | 2020-01-16 | 2021-07-22 | 浙江海正药业股份有限公司 | 杂芳基类衍生物及其制备方法和用途 |
AR121683A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
AR121682A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
WO2021233428A1 (zh) * | 2020-05-21 | 2021-11-25 | 广州费米子科技有限责任公司 | 含氮饱和杂环化合物及其制备方法、药物组合物和应用 |
EP4206175A1 (en) * | 2020-08-24 | 2023-07-05 | Hua Medicine (Shanghai) Ltd. | Preparation of substituted acrylate compound |
CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药(上海)有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
WO2023187677A1 (en) * | 2022-03-30 | 2023-10-05 | Takeda Pharmaceutical Company Limited | N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
CN1960970A (zh) * | 2004-05-28 | 2007-05-09 | 田边制药株式会社 | 作为cb1受体的拮抗剂的吡咯烷衍生物 |
EP2338881A1 (en) | 2005-02-23 | 2011-06-29 | Prexa Pharmaceuticals, Inc. | Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications |
DK1893603T3 (da) | 2005-06-02 | 2009-11-30 | Hoffmann La Roche | Piperidin-4-YL-amidderivater og anvendelsen deraf som SST-receptorundertype 5-antagonister |
JP4943826B2 (ja) * | 2005-11-25 | 2012-05-30 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
EP2280966A1 (en) | 2008-03-14 | 2011-02-09 | Exelixis, Inc. | Azabicyclo [3.2.1]octyl derivatives as 11 beta-hsd1 modulators |
WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
KR20120049940A (ko) | 2009-09-04 | 2012-05-17 | 노파르티스 아게 | 키나제 억제제로서의 헤테로아릴 화합물 |
US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
JPWO2015037716A1 (ja) * | 2013-09-12 | 2017-03-02 | 住友化学株式会社 | 含窒素飽和複素環化合物 |
KR20170082632A (ko) | 2014-11-14 | 2017-07-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 소마토스타틴 수용체 아형 4 (sstr4) 작용제로서의 모르폴린 및 1,4-옥사제판 아미드 |
JP2015037716A (ja) | 2014-11-27 | 2015-02-26 | 株式会社大一商会 | 遊技機 |
EP3317277B1 (en) | 2015-07-01 | 2021-01-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
TWI834637B (zh) * | 2018-03-01 | 2024-03-11 | 日商武田藥品工業有限公司 | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 |
-
2019
- 2019-02-27 TW TW108106689A patent/TWI834637B/zh active
- 2019-02-28 JP JP2020545526A patent/JP7297776B2/ja active Active
- 2019-02-28 CN CN201980026854.8A patent/CN112236423B/zh active Active
- 2019-02-28 BR BR112020017644-3A patent/BR112020017644A2/pt unknown
- 2019-02-28 EP EP19710934.1A patent/EP3759094A1/en active Pending
- 2019-02-28 AU AU2019228568A patent/AU2019228568A1/en active Pending
- 2019-02-28 AR ARP190100507A patent/AR114421A1/es unknown
- 2019-02-28 UA UAA202005559A patent/UA126829C2/uk unknown
- 2019-02-28 KR KR1020207028006A patent/KR20200138245A/ko not_active Application Discontinuation
- 2019-02-28 CA CA3092450A patent/CA3092450A1/en active Pending
- 2019-02-28 US US16/289,311 patent/US11045457B2/en active Active
- 2019-02-28 WO PCT/US2019/020086 patent/WO2019169153A1/en active Application Filing
- 2019-02-28 SG SG11202008398XA patent/SG11202008398XA/en unknown
- 2019-02-28 IL IL276998A patent/IL276998B2/en unknown
- 2019-02-28 PE PE2020001318A patent/PE20211313A1/es unknown
- 2019-02-28 EA EA202092054A patent/EA202092054A1/ru unknown
- 2019-02-28 MX MX2020009062A patent/MX2020009062A/es unknown
-
2020
- 2020-08-29 PH PH12020551359A patent/PH12020551359A1/en unknown
- 2020-08-31 ZA ZA2020/05438A patent/ZA202005438B/en unknown
- 2020-09-01 CL CL2020002257A patent/CL2020002257A1/es unknown
- 2020-10-01 EC ECSENADI202062464A patent/ECSP20062464A/es unknown
-
2021
- 2021-05-14 US US17/320,574 patent/US12005054B2/en active Active
-
2023
- 2023-06-14 JP JP2023098091A patent/JP2023134444A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
UA126829C2 (uk) | 2023-02-08 |
WO2019169153A1 (en) | 2019-09-06 |
CL2020002257A1 (es) | 2021-01-29 |
JP2021515004A (ja) | 2021-06-17 |
TWI834637B (zh) | 2024-03-11 |
US12005054B2 (en) | 2024-06-11 |
IL276998A (en) | 2020-10-29 |
CN112236423A (zh) | 2021-01-15 |
MX2020009062A (es) | 2020-10-12 |
EP3759094A1 (en) | 2021-01-06 |
SG11202008398XA (en) | 2020-09-29 |
TW202000659A (zh) | 2020-01-01 |
BR112020017644A2 (pt) | 2021-01-19 |
IL276998B1 (en) | 2023-10-01 |
US20200061041A1 (en) | 2020-02-27 |
JP7297776B2 (ja) | 2023-06-26 |
EA202092054A1 (ru) | 2021-01-22 |
US11045457B2 (en) | 2021-06-29 |
IL276998B2 (en) | 2024-02-01 |
CN112236423B (zh) | 2024-02-06 |
CA3092450A1 (en) | 2019-09-06 |
ZA202005438B (en) | 2023-02-22 |
ECSP20062464A (es) | 2020-12-31 |
JP2023134444A (ja) | 2023-09-27 |
AR114421A1 (es) | 2020-09-02 |
PH12020551359A1 (en) | 2021-08-23 |
AU2019228568A1 (en) | 2020-09-24 |
KR20200138245A (ko) | 2020-12-09 |
US20230021834A1 (en) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211313A1 (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos | |
AR064355A1 (es) | Herbicidas derivados de isoxazol | |
PE20211050A1 (es) | Inhibidores de ptpn11 | |
AR067823A1 (es) | Compuestos de amina ciclica | |
AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
AR117923A2 (es) | Compuestos 4-amino-6-(4-fenilo sustituido)-picolinatos y 6-amino-2-(4-fenilo sustituido)-pirimidin-4-carboxilatos y composición que los comprende | |
AR054130A1 (es) | Procedimiento para la preparacion de 1-alquil-3-feniluracilos | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
ECSP12012212A (es) | Derivados de ariletinilo | |
AR066946A1 (es) | Compuestos heterociclicos antagonistas del receptor de histamina h3, y sus usos terapeuticos | |
CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
PE20081851A1 (es) | Derivados de espiropiperidina-glicinamida | |
PE20221083A1 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso | |
CY1116391T1 (el) | Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5 | |
EA201600403A1 (ru) | N-ацилиминогетероциклические соединения | |
PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
PE20160050A1 (es) | Inhibidores/ antiandrogenos novedosos de cyp17 | |
PE20191082A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
AR075951A1 (es) | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek | |
CO6321269A2 (es) | Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios | |
AR102731A1 (es) | Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor |